Intuitive Surgical, Inc. (NASDAQ:ISRG) is a leader in robotic-assisted surgery, known for its innovative da Vinci surgical systems. These systems allow surgeons to perform complex procedures with precision and minimal invasiveness, improving patient outcomes. The company faces competition from other medical device manufacturers but maintains a strong market position due to its advanced technology and continuous innovation.
As Intuitive Surgical prepares to release its quarterly earnings on October 21, 2025, analysts expect an EPS of $1.99 and revenue of approximately $2.41 billion. This growth is largely driven by the increasing adoption of the da Vinci 5 system and a projected 15.5-17% rise in worldwide da Vinci procedures in 2025. The company's strong fundamentals are evident in its robust revenue growth and high margins.
Despite these positive indicators, Intuitive Surgical faces challenges such as tariff risks and global capital expenditure constraints, which could limit its upside potential. Additionally, while the da Vinci 5 and Ion systems have contributed positively, weaknesses in the bariatric segment may offset some gains. Rising component costs and increased R&D expenditures may also pressure margins.
Intuitive Surgical's market capitalization stands at $156 billion, with a revenue of $9.1 billion and operating profits of $2.6 billion over the past year. The company has demonstrated impressive revenue growth, with a 20.8% increase over the last twelve months. Its operating cash flow margin is nearly 30.9%, and the operating margin is 28.8%, showcasing its profitability.
The stock is currently trading at a price-to-sales multiple of 17.1, a 26% discount compared to a year ago. This, combined with its high margins and pricing power, results in consistent profits and cash flows. Intuitive Surgical's strong liquidity, indicated by a current ratio of 5.17, further supports its financial stability and ability to reinvest capital effectively.
